Recruiting
Phase 2

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing

Sponsor:

Esperion Therapeutics, Inc.

Code:

NCT05694260

Conditions

Hypercholesterolemia

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Bempedoic acid

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information